2021 AHA科学声明：药物依从性和血压控制

2021-10-07 美国心脏协会 Hypertension 发表于上海

2021年10月，美国心脏协会(AHA)发布了药物依从性和血压控制的科学声明。

中文标题：

英文标题：

Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association

发布机构：

美国心脏协会

发布日期：

2021-10-07

简要介绍：

2021年10月，美国心脏协会(AHA)发布了药物依从性和血压控制的科学声明。高血压的广泛治疗以及由此带来的血压改善是导致心脏和卒中发病率显著下降的主要原因，本文主要总结了药物不依从性对于血压控制不良的影响，检测药物依从性的方法及挑战，抗高血压药物不依从性的危险因素以及个人和卫生系统层面提高抗高血压药物依从性的策略。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=f04251c002200e7a, title=2021 AHA科学声明：药物依从性和血压控制 , enTitle=Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association, guiderFrom=Hypertension, authorId=0, author=, summary=2021年10月，美国心脏协会(AHA)发布了药物依从性和血压控制的科学声明。, cover=https://img.medsci.cn/2021109/1633749865379_5579292.jpg, journalId=0, articlesId=null, associationId=60, associationName=美国心脏协会, associationIntro=美国心脏协会（AHA，American Heart Association）是心脏病学领域比较正要的学会之一，致力于心脏病和卒中的预防与治疗，提供相关继续教育、流行病学年度报告。每年举办学术年会报道中的的临床试验结果等，有官方杂志《美国心脏协会杂志》，提供心血管疾病和卒中相关的指南及专家共识，更新的比较快。, copyright=0, guiderPublishedTime=Thu Oct 07 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年10月，美国心脏协会(AHA)发布了药物依从性和血压控制的科学声明。高血压的广泛治疗以及由此带来的血压改善是导致心脏和卒中发病率显著下降的主要原因，本文主要总结了药物不依从性对于血压控制不良的影响，检测药物依从性的方法及挑战，抗高血压药物不依从性的危险因素以及个人和卫生系统层面提高抗高血压药物依从性的策略。</span></p>, tagList=[TagDto(tagId=48082, tagName=药物依从性)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=48082, guiderKeyword=药物依从性, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3333, appHits=113, showAppHits=0, pcHits=1185, showPcHits=3219, likes=0, shares=7, comments=10, approvalStatus=1, publishedTime=Sat Oct 09 12:07:30 CST 2021, publishedTimeString=2021-10-07, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Oct 09 11:24:49 CST 2021, updatedBy=6459136, updatedName=玉在山, updatedTime=Sat Jan 06 22:32:23 CST 2024, courseDetails=[], otherVersionGuiders=[OtherVersionToolGuiderDto(projectId=1, id=a65801c00289e6da, title=【中文译文】2021 AHA科学声明：药物依从性和血压控制 , enTitle=Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association, guiderPublishedTime=Thu Oct 07 00:00:00 CST 2021, createdTime=Fri Dec 30 16:36:44 CST 2022)], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 AHA科学声明：药物依从性和血压控制.pdf)])

2021 AHA科学声明：药物依从性和血压控制.pdf

下载请点击：

其他版本

【中文译文】2021 AHA科学声明：药物依从性和血压控制

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1179042, encodeId=720811e904217, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=906d1971797, createdName=ms3342259277908373, createdTime=Fri Dec 31 03:19:23 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077554, encodeId=213210e755471, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de76387920, createdName=ms1000000361702375, createdTime=Mon Dec 06 22:45:42 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074204, encodeId=70fa10e42046a, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:33 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063585, encodeId=0f4a106358578, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee95582917, createdName=唐唐露露, createdTime=Sun Oct 24 21:47:34 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060997, encodeId=eb61106099ebc, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b85637570, createdName=ms1000001425856682, createdTime=Sat Oct 16 11:31:35 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
2021-12-31 ms3342259277908373

一起学习了

53 0
[GetPortalCommentsPageByObjectIdResponse(id=1179042, encodeId=720811e904217, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=906d1971797, createdName=ms3342259277908373, createdTime=Fri Dec 31 03:19:23 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077554, encodeId=213210e755471, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de76387920, createdName=ms1000000361702375, createdTime=Mon Dec 06 22:45:42 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074204, encodeId=70fa10e42046a, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:33 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063585, encodeId=0f4a106358578, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee95582917, createdName=唐唐露露, createdTime=Sun Oct 24 21:47:34 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060997, encodeId=eb61106099ebc, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b85637570, createdName=ms1000001425856682, createdTime=Sat Oct 16 11:31:35 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
2021-12-06 ms1000000361702375

一起学习了

47 0
[GetPortalCommentsPageByObjectIdResponse(id=1179042, encodeId=720811e904217, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=906d1971797, createdName=ms3342259277908373, createdTime=Fri Dec 31 03:19:23 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077554, encodeId=213210e755471, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de76387920, createdName=ms1000000361702375, createdTime=Mon Dec 06 22:45:42 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074204, encodeId=70fa10e42046a, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:33 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063585, encodeId=0f4a106358578, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee95582917, createdName=唐唐露露, createdTime=Sun Oct 24 21:47:34 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060997, encodeId=eb61106099ebc, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b85637570, createdName=ms1000001425856682, createdTime=Sat Oct 16 11:31:35 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
2021-11-26 H8888888

不错学习了

65 0
[GetPortalCommentsPageByObjectIdResponse(id=1179042, encodeId=720811e904217, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=906d1971797, createdName=ms3342259277908373, createdTime=Fri Dec 31 03:19:23 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077554, encodeId=213210e755471, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de76387920, createdName=ms1000000361702375, createdTime=Mon Dec 06 22:45:42 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074204, encodeId=70fa10e42046a, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:33 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063585, encodeId=0f4a106358578, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee95582917, createdName=唐唐露露, createdTime=Sun Oct 24 21:47:34 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060997, encodeId=eb61106099ebc, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b85637570, createdName=ms1000001425856682, createdTime=Sat Oct 16 11:31:35 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
2021-10-24 唐唐露露

一起学习了

80 0
[GetPortalCommentsPageByObjectIdResponse(id=1179042, encodeId=720811e904217, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=906d1971797, createdName=ms3342259277908373, createdTime=Fri Dec 31 03:19:23 CST 2021, time=2021-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077554, encodeId=213210e755471, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4de76387920, createdName=ms1000000361702375, createdTime=Mon Dec 06 22:45:42 CST 2021, time=2021-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1074204, encodeId=70fa10e42046a, content=不错学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Fri Nov 26 14:10:33 CST 2021, time=2021-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063585, encodeId=0f4a106358578, content=一起学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ee95582917, createdName=唐唐露露, createdTime=Sun Oct 24 21:47:34 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060997, encodeId=eb61106099ebc, content=一起学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41b85637570, createdName=ms1000001425856682, createdTime=Sat Oct 16 11:31:35 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
2021-10-16 ms1000001425856682

一起学习

103 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

2021 AHA科学声明：药物依从性和血压控制

【中文译文】2021 AHA科学声明：药物依从性和血压控制

相关指南

拓展阅读

科室

工具

服务